256 related articles for article (PubMed ID: 11228084)
21. Long-term therapy with policosanol improves treadmill exercise-ECG testing performance of coronary heart disease patients.
Stüsser R; Batista J; Padrón R; Sosa F; Pereztol O
Int J Clin Pharmacol Ther; 1998 Sep; 36(9):469-73. PubMed ID: 9760006
[TBL] [Abstract][Full Text] [Related]
22. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study.
Castaño G; Mas R; Fernández L; Illnait J; Gámez R; Alvarez E
Int J Clin Pharmacol Res; 2001; 21(1):43-57. PubMed ID: 11708574
[TBL] [Abstract][Full Text] [Related]
23. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients.
Castaño G; Más R; Arruzazabala ML; Noa M; Illnait J; Fernández JC; Molina V; Menéndez A
Int J Clin Pharmacol Res; 1999; 19(4):105-16. PubMed ID: 10939028
[TBL] [Abstract][Full Text] [Related]
24. Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial.
Balsano F; Coccheri S; Libretti A; Nenci GG; Catalano M; Fortunato G; Grasselli S; Violi F; Hellemans H; Vanhove P
J Lab Clin Med; 1989 Jul; 114(1):84-91. PubMed ID: 2661700
[TBL] [Abstract][Full Text] [Related]
25. A randomized trial of iloprost in patients with intermittent claudication.
Creager MA; Pande RL; Hiatt WR
Vasc Med; 2008 Feb; 13(1):5-13. PubMed ID: 18372433
[TBL] [Abstract][Full Text] [Related]
26. A randomized, double-blind, placebo-controlled, crossover study to assess the immediate effect of sublingual glyceryl trinitrate on the ankle brachial pressure index, claudication, and maximum walking distance of patients with intermittent claudication.
Walker SR; Tennant S; MacSweeney ST
J Vasc Surg; 1998 Nov; 28(5):895-900. PubMed ID: 9808859
[TBL] [Abstract][Full Text] [Related]
27. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial.
Mohler ER; Hiatt WR; Olin JW; Wade M; Jeffs R; Hirsch AT
J Am Coll Cardiol; 2003 May; 41(10):1679-86. PubMed ID: 12767646
[TBL] [Abstract][Full Text] [Related]
28. Reliability of treadmill testing in peripheral arterial disease: a comparison of a constant load with a graded load treadmill protocol.
Labs KH; Nehler MR; Roessner M; Jaeger KA; Hiatt WR
Vasc Med; 1999; 4(4):239-46. PubMed ID: 10613628
[TBL] [Abstract][Full Text] [Related]
29. Improvement of walking distance by defibrotide in patients with intermittent claudication--results of a randomized, placebo-controlled study (the DICLIS study). Defibrotide Intermittent CLaudication Italian Study.
Violi F; Marubini E; Coccheri S; Nenci GG
Thromb Haemost; 2000 May; 83(5):672-7. PubMed ID: 10823260
[TBL] [Abstract][Full Text] [Related]
30. Antiplatelet effects of policosanol (20 and 40 mg/day) in healthy volunteers and dyslipidaemic patients.
Arruzazabala ML; Molina V; Mas R; Fernández L; Carbajal D; Valdés S; Castaño G
Clin Exp Pharmacol Physiol; 2002 Oct; 29(10):891-7. PubMed ID: 12207568
[TBL] [Abstract][Full Text] [Related]
31. Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients.
Arruzazabala ML; Más R; Molina V; Carbajal D; Mendoza S; Fernández L; Valdés S
Int J Tissue React; 1998; 20(4):119-24. PubMed ID: 10093795
[TBL] [Abstract][Full Text] [Related]
32. Effect on walking distance and atherosclerosis progression of a nitric oxide-donating agent in intermittent claudication.
Gresele P; Migliacci R; Arosio E; Bonizzoni E; Minuz P; Violi F;
J Vasc Surg; 2012 Dec; 56(6):1622-8, 1628.e1-5. PubMed ID: 22963812
[TBL] [Abstract][Full Text] [Related]
33. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors.
Más R; Castaño G; Illnait J; Fernández L; Fernández J; Alemán C; Pontigas V; Lescay M
Clin Pharmacol Ther; 1999 Apr; 65(4):439-47. PubMed ID: 10223782
[TBL] [Abstract][Full Text] [Related]
34. Treatment of intermittent claudication with mesoglycan--a placebo-controlled, double-blind study.
Nenci GG; Gresele P; Ferrari G; Santoro L; Gianese F;
Thromb Haemost; 2001 Nov; 86(5):1181-7. PubMed ID: 11816704
[TBL] [Abstract][Full Text] [Related]
35. Heparan sulfate in the treatment of intermittent claudication: results of a randomized, double-blind, placebo-controlled multicenter trial.
Messa GL; Gelso E
Drugs Exp Clin Res; 2002; 28(1):37-48. PubMed ID: 12073766
[TBL] [Abstract][Full Text] [Related]
36. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS).
Kieffer E; Bahnini A; Mouren X; Gamand S
Int Angiol; 2001 Mar; 20(1):58-65. PubMed ID: 11342997
[TBL] [Abstract][Full Text] [Related]
37. Ketanserin in intermittent claudication. A double-blind placebo-controlled study.
Clement DL; Duprez D; Van Wassenhove A; Brusselmans F
Int Angiol; 1989; 8(2):92-6. PubMed ID: 2681451
[TBL] [Abstract][Full Text] [Related]
38. Treatment of intermittent claudication with pentoxifylline: a 12-month, randomized trial--walking distance and microcirculation.
De Sanctis MT; Cesarone MR; Belcaro G; Nicolaides AN; Griffin M; Incandela L; Bucci M; Geroulakos G; Ramaswami G; Vasdekis S; Agus G; Bavera P; Ippolito E
Angiology; 2002; 53 Suppl 1():S7-12. PubMed ID: 11865838
[TBL] [Abstract][Full Text] [Related]
39. Effects of ethaverine hydrochloride on the walking tolerance of patients with intermittent claudication.
Trainor FS; Phillips RE; Michie DD; Zellner SR; Hogan L; Chubb JM
Angiology; 1986 May; 37(5):343-51. PubMed ID: 3521401
[TBL] [Abstract][Full Text] [Related]
40. Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group.
Lièvre M; Morand S; Besse B; Fiessinger JN; Boissel JP
Circulation; 2000 Jul; 102(4):426-31. PubMed ID: 10908215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
